Sullivan, Ryan J. http://orcid.org/0000-0001-5344-6645
Hamid, Omid
Gonzalez, Rene
Infante, Jeffrey R.
Patel, Manish R.
Hodi, F. Stephen
Lewis, Karl D.
Tawbi, Hussein A.
Hernandez, Genevive
Wongchenko, Matthew J. http://orcid.org/0000-0003-1230-7117
Chang, YiMeng
Roberts, Louise
Ballinger, Marcus
Yan, Yibing
Cha, Edward
Hwu, Patrick
Article History
Received: 20 February 2019
Revised: 18 April 2019
Accepted: 30 April 2019
First Online: 6 June 2019
Competing interests
: This study was funded by F. Hoffman-La Roche Ltd. R.J.S. reports personal fees from Amgen, Merck, Genentech, Array and Novartis; research grants from Amgen and Merck; and clinical trial support from Merck, Genentech and Novartis during the conduct of the study; and by personal fees from Compugen, Replimune and Syndax outside the submitted work. O.H. reports advisory board fees from Roche and speaker bureau fees from Genentech during the conduct of the study; advisory board fees from Amgen, Novartis and Bristol-Myers Squibb; speaker bureau fees from Amgen, Bristol-Myers Squibb, Novartis and Array Biopharma; and research support paid to institution from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Merck Serono, MedImmune, Novartis, Pfizer, Rinat and Roche outside the submitted work. R.G. reports personal fees and grants from Roche/Genentech during the conduct of the study, personal fees and grants from Bristol-Myers Squibb and Novartis; and grants from Merck and Array Biopharma outside the submitted work. J.R.I. reports consultancy fees from BioMed Valley and Armo Biosciences and employment with Janssen Pharmaceuticals outside the submitted work. M.R.P. reports no competing interests. F.S.H. reports clinical trial support paid to institution from Genentech during the conduct of the study; consultancy fees from Genentech, Merck, Novartis, Bristol-Myers Squibb, Aduro, Partner Therapeutics, EMD Serono, Sanofi and Celldex; advisory board fees from Apricity; and research grants paid to institution from Bristol-Myers Squibb outside the submitted work; F.S.H. also reports an issued patent for Therapeutic Peptides and pending patents for MICA Related Disorders and Angiopoietin-2 as Therapeutic Target for Cancer. K.D.L. reports grants from Roche/Genentech during the conduct of the study and consultancy fees from Roche/Genentech outside the submitted work. H.A.T. reports grants and personal fees from Roche/Genentech during the conduct of the study; and grants and personal fees from Bristol-Myers Squibb, Merck and Novartis outside the submitted work. G.H. reports employment with Roche. M.J.W. reports employment and stock ownership with Genentech/Roche and stock ownership with ARIAD Pharmaceuticals. Y.C. reports employment with Genentech/Roche. L.R. reports employment with Genentech/Roche. M.B. reports employment and stock ownership with Genentech/Roche. Y.Y. reports employment with Genentech/Roche and stock ownership with Genentech/Roche. E.C. reports employment and stock ownership with Genentech/Roche. P.H. reports consultancy and advisory fees from Dragonfly, GlaxoSmithKline, Immatics and Sanofi outside the submitted work.